Mark Wegter, economist, joined LSP in 1998 and became a general partner in early 2001. He currently serves as Chairman of the supervisory board of Kiadis Pharma (NL/CDN) and as a supervisory board member for PamGene (NL), OncoMethylome Sciences (B), 4-Antibody (CH/G) and EyeSense (CH/G). He was also on the Supervisory Board of Jerini (G) until the company was listed on the Frankfurt stock exchange in November 2005. Mark has been involved in many of LSPâ€™s investments, both early- and later-stage, including U-BiSys (NL) (which became Crucell after it merged with yet another of LSPâ€™s portfolio companies), deVGen (B) (which was listed on the Euronext stock exchange in 2005), De Novo Pharmaceuticals (UK) and Kreatech Biotechnology (NL). He established LSPâ€™s Munich office in late 2001 and has since extended LSPâ€™s foothold in Germany and Switzerland, together with Joachim Rothe.
Mark started his career at ING Barings Investment Banking in Amsterdam and SÃ£o Paulo, where he worked as a senior analyst on Global Risk Management and served as the assistant to a member of the executive committee, with worldwide responsibility for risk management. Mark has a Masters degree in business economics from the Erasmus University of Rotterdam.